(no title)

OUR SERVICES

Biogecho Consulting, founded in 2009, is a pharmaceutical regulatory affairs consulting business based in Geneva, Switzerland. Its Core activities revolve around International Regulatory Affairs and Development Strategy of Drugs, Medical Devices and Cosmetics. Our Business provides a service that is professional, high quality, flexible and solution based to meet all our clients and partners needs. We understand both the commercial aspects and the unmet medical needs of our Clients various products and we are committed to getting their products to the market in a fast and efficient manner.

Drug development strategy

Product development of orphan drugs, Pharmaceutical (Biotech, NBE, ATMPs, vaccines, generics, biosimilars, plasma-derived products and cosmetics.

Medical devices

Biogecho has a well-established presence in the EU, with offices in Switzerland and in France. We have assisted several medical device manufacturers with compliance in Europe.

Cosmetics

European cosmetics regulations continue to tighten as authorities seek to ensure the safety of consumers—and as they demand greater transparency around products and their ingredients. The result is that pharmaceutical companies must provide both safety and toxicological data on the substances in their products.

Other Services

We can provide assistance as a consultant, an advisor, a temporary staff and as a trainor.

SWISSMEDIC

Swissmedic is the Swiss authority for the licensing and monitoring of therapeutic products.

ICH

The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration.

EMA

The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in London. It began operating in 1995. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU.